Enlicitide Decanoate (Lipfendra), CORALreef
LDL-cholesterol lowering — first oral PCSK9 inhibitor
Sponsor: Merck (MSD)
- 14,550Enrollment target
- N/ATrial sites
- N/ACountries
- November 2029Est. completion
- NCT06008756Registry record
About this trial
First once-daily oral PCSK9 inhibitor, approved on LDL lowering while a 14,550-patient cardiovascular outcomes trial continues.
Primary endpoints
- Percentage change in LDL cholesterol
- Major adverse cardiovascular events
Latest update
July 2026
The FDA approved enlicitide decanoate as Lipfendra, which Merck describes as the first and only once-daily oral PCSK9 inhibitor, for lowering LDL cholesterol. The CORALreef Outcomes cardiovascular trial continues to a 2029 primary completion.
SourceTrial information is compiled from public sources and may be out of date. It is not medical advice and is not an offer of enrolment; check the registry entry or speak to a physician before acting on it.